MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

53.94
+1.11
+2.10%
After Hours: 53.94 0 0.00% 16:19 09/17 EDT
OPEN
53.42
PREV CLOSE
52.83
HIGH
53.98
LOW
52.75
VOLUME
941.60K
TURNOVER
--
52 WEEK HIGH
99.00
52 WEEK LOW
43.66
MARKET CAP
2.51B
P/E (TTM)
-40.6695
1D
5D
1M
3M
1Y
5Y
Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos
Benzinga · 4d ago
Glaukos settles patent dispute with Ivantis over glaucoma microstent
Ivantis will pay $60M as well as a double-digit royalty to Glaukos (NYSE:GKOS) to settle a patent infringement lawsuit Glaukos lodged against Ivantis regarding the latter's Hydrus Microstent. $30M will be paid
Seekingalpha · 4d ago
BRIEF-Glaukos Settles Patent Litigation With Ivantis
reuters.com · 4d ago
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
SAN CLEMENTE, Calif., September 15, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that i...
Business Wire · 4d ago
Glaukos Agrees to Stop Patent Litigation Against Ivantis in Exchange for $60 Million Payment, Royalty Share
MT Newswires · 4d ago
Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform
Zacks.com · 09/09 13:24
Here’s Why Artisan Partners Sold its Glaukos Corporation (GKOS) Position
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 4.36% was recorded by its Investor Class: ARTSX, 4.40% by its ...
Insider Monkey · 09/06 17:29
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Benzinga · 09/03 13:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GKOS. Analyze the recent business situations of Glaukos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GKOS stock price target is 51.67 with a high estimate of 65.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 317
Institutional Holdings: 62.14M
% Owned: 133.47%
Shares Outstanding: 46.56M
TypeInstitutionsShares
Increased
83
2.36M
New
32
947.05K
Decreased
64
2.68M
Sold Out
28
192.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
William Link
President/Chief Executive Officer/Director
Thomas Burns
Chief Financial Officer/Senior Vice President
Joseph Gilliam
Chief Operating Officer
Chris Calcaterra
Independent Director
Mark Foley
Independent Director
David Hoffmeister
Independent Director
Gilbert Kliman
Independent Director
Marc Stapley
Independent Director
Denice Torres
Independent Director
Aimee Weisner
Independent Director
Leana Wen
No Data
About GKOS
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.